

Protalix BioTherapeutics, Inc.  
Form 8-K  
November 22, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 22, 2016**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**                                      **001-33357**                                      **65-0643773**  
**(State or other jurisdiction**                                      **(Commission File Number)**                                      **(IRS Employer**  
**of incorporation)**                                      **Identification No.)**

**2 Snunit Street**                                      **20100**  
**Science Park, POB 455**  
**Carmiel, Israel**  
**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code +972-4-988-9488**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On November 22, 2016, Protalix BioTherapeutics, Inc. issued a press release announcing that the Brazilian National Health Surveillance Agency (ANVISA, Agencia Nacional de Vigilancia Sanitaria) has granted regulatory approval for alfataliglicerase as a long-term enzyme replacement therapy for children four years old and above with a confirmed diagnosis of Type I Gaucher disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated November 22, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX  
BIOTHERAPEUTICS, INC.**

Date: November 22, 2016 By: /s/ Moshe Manor  
Name: Moshe Manor  
Title: President and  
Chief Executive Officer